表紙
市場調査レポート

副腎白質ジストロフィー:世界の治験動向

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2015

発行 GlobalData 商品コード 340879
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
副腎白質ジストロフィー:世界の治験動向 Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2015
出版日: 2015年08月31日 ページ情報: 英文 70 Pages
概要

副腎白質ジストロフィーは、中枢神経系 (脳や脊髄) における脱髄や副腎の機能不全を特徴とする遺伝性疾患です。

当レポートでは、副腎白質ジストロフィーの治験に関する最新動向について分析しており、各地域の主要国における治験件数、治験の段階別進行状況、被験者採用の状況、有望なスポンサー、各企業や研究機関における研究の進行状況、有望な薬剤の比較といった情報をまとめています。

イントロダクション

  • 副腎白質ジストロフィー
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要国における治験件数
    • 欧州の主要国における治験件数
    • 北米の主要国における治験件数

G7諸国での治験件数:遺伝性疾患治療薬の治験における副腎白質ジストロフィーの割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:遺伝性疾患治療薬の治験における副腎白質ジストロフィーの割合

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

未完了の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

副腎白質ジストロフィー治療薬の治験に携わっている主要企業

有望な薬剤

治験のプロファイル

  • 主要企業の治験の概要
    • Bluebird bio, Inc.
    • Aldagen, Inc. (Inactive)
    • NUVISAN GmbH
    • Nutra Pharma Corporation
    • Nuo Therapeutics, Inc.
    • Neuralgene
    • Marcus Foundation Inc
    • Fate Therapeutics, Inc.
    • Celgene Corporation
    • Asklepion Pharmaceuticals, LLC
  • 代表的な研究機関・病院の治験の概要
    • Duke University
    • Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
    • Academic Medical Center
    • Far Eastern Memorial Hospital
    • FDA Office of Orphan Products Development
    • Herbert Irving Comprehensive Cancer Center
    • Institute of Biomedical Investigations of Bellvitge
    • Masonic Cancer Center

5つの代表的な治験のプロファイル

付録

目次
Product Code: GDHC2846CTIDB

GlobalData's clinical trial report, "Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2015" provides an overview of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) clinical trials scenario. This report provides top line data relating to the clinical trials on Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex)
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
  • Clinical Trials by G7 Countries: Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex)
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Bluebird bio, Inc.
      • Clinical Trial Overview of Bluebird bio, Inc.
      • Aldagen, Inc. (Inactive)
      • Clinical Trial Overview of Aldagen, Inc. (Inactive)
      • NUVISAN GmbH
      • Clinical Trial Overview of NUVISAN GmbH
      • Nutra Pharma Corporation
      • Clinical Trial Overview of Nutra Pharma Corporation
      • Nuo Therapeutics, Inc.
      • Clinical Trial Overview of Nuo Therapeutics, Inc.
      • Neuralgene
      • Clinical Trial Overview of Neuralgene
      • Marcus Foundation Inc
      • Clinical Trial Overview of Marcus Foundation Inc
      • Fate Therapeutics, Inc.
      • Clinical Trial Overview of Fate Therapeutics, Inc.
      • Celgene Corporation
      • Clinical Trial Overview of Celgene Corporation
      • Asklepion Pharmaceuticals, LLC
      • Clinical Trial Overview of Asklepion Pharmaceuticals, LLC
    • Clinical Trial Overview of Top Institutes / Government
      • Duke University
      • Clinical Trial Overview of Duke University
      • Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
      • Clinical Trial Overview of Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
      • Academic Medical Center
      • Clinical Trial Overview of Academic Medical Center
      • Far Eastern Memorial Hospital
      • Clinical Trial Overview of Far Eastern Memorial Hospital
      • FDA Office of Orphan Products Development
      • Clinical Trial Overview of FDA Office of Orphan Products Development
      • Herbert Irving Comprehensive Cancer Center
      • Clinical Trial Overview of Herbert Irving Comprehensive Cancer Center
      • Institute of Biomedical Investigations of Bellvitge
      • Clinical Trial Overview of Institute of Biomedical Investigations of Bellvitge
      • Masonic Cancer Center
      • Clinical Trial Overview of Masonic Cancer Center
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Region, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Europe, Top Countries, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, North America, Top Countries, 2015*
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, G7 Countries (%), 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, E7 Countries (%), 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Phase, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Phase 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Suspended Clinical Trials, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Withdrawn Clinical Trials, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Terminated Clinical Trials, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Bluebird bio, Inc., 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Aldagen, Inc. (Inactive), 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by NUVISAN GmbH, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nutra Pharma Corporation, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nuo Therapeutics, Inc., 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Neuralgene, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Marcus Foundation Inc, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fate Therapeutics, Inc., 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Asklepion Pharmaceuticals, LLC, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Hugo W. Moser Research Institute at Kennedy Krieger, Inc., 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Academic Medical Center, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Far Eastern Memorial Hospital, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by FDA Office of Orphan Products Development, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Herbert Irving Comprehensive Cancer Center, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Institute of Biomedical Investigations of Bellvitge, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market, Global, Clinical Trials by Masonic Cancer Center, 2015*

List of Figures

  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Region (%), 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Europe, Top Countries (%), 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, North America, Top Countries (%), 2015*
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, G7 Countries (%), 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders Clinical Trials, E7 Countries (%), 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Phase (%), 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • GlobalData Methodology
Back to Top